1359 related articles for article (PubMed ID: 26700815)
1. Insulator dysfunction and oncogene activation in IDH mutant gliomas.
Flavahan WA; Drier Y; Liau BB; Gillespie SM; Venteicher AS; Stemmer-Rachamimov AO; Suvà ML; Bernstein BE
Nature; 2016 Jan; 529(7584):110-4. PubMed ID: 26700815
[TBL] [Abstract][Full Text] [Related]
2. Bringing IDH into the Fold.
Zadeh G; Aldape K
Cancer Cell; 2016 Feb; 29(2):139-40. PubMed ID: 26859452
[TBL] [Abstract][Full Text] [Related]
3. Modeling epigenetic lesions that cause gliomas.
Rahme GJ; Javed NM; Puorro KL; Xin S; Hovestadt V; Johnstone SE; Bernstein BE
Cell; 2023 Aug; 186(17):3674-3685.e14. PubMed ID: 37494934
[TBL] [Abstract][Full Text] [Related]
4. Oncometabolite Tinkers with Genome Folding, Boosting Oncogene Expression.
Ing-Simmons E; Merkenschlager M
Trends Mol Med; 2016 Mar; 22(3):185-187. PubMed ID: 26856236
[TBL] [Abstract][Full Text] [Related]
5. Disruption of CTCF/cohesin-mediated high-order chromatin structures by DNA methylation downregulates PTGS2 expression.
Kang JY; Song SH; Yun J; Jeon MS; Kim HP; Han SW; Kim TY
Oncogene; 2015 Nov; 34(45):5677-84. PubMed ID: 25703332
[TBL] [Abstract][Full Text] [Related]
6. CNS cancer: Breaking boundaries - IDH mutations in glioma.
Killock D
Nat Rev Clin Oncol; 2016 Feb; 13(2):64. PubMed ID: 26787277
[No Abstract] [Full Text] [Related]
7. Partial erosion on under-methylated regions and chromatin reprogramming contribute to oncogene activation in IDH mutant gliomas.
Wang X; Dai L; Liu Y; Li C; Fan D; Zhou Y; Li P; Kong Q; Su J
Epigenetics Chromatin; 2023 Apr; 16(1):13. PubMed ID: 37118755
[TBL] [Abstract][Full Text] [Related]
8. IGFBP2 expression predicts IDH-mutant glioma patient survival.
Huang LE; Cohen AL; Colman H; Jensen RL; Fults DW; Couldwell WT
Oncotarget; 2017 Jan; 8(1):191-202. PubMed ID: 27852048
[TBL] [Abstract][Full Text] [Related]
9. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Turcan S; Rohle D; Goenka A; Walsh LA; Fang F; Yilmaz E; Campos C; Fabius AW; Lu C; Ward PS; Thompson CB; Kaufman A; Guryanova O; Levine R; Heguy A; Viale A; Morris LG; Huse JT; Mellinghoff IK; Chan TA
Nature; 2012 Feb; 483(7390):479-83. PubMed ID: 22343889
[TBL] [Abstract][Full Text] [Related]
10. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
[TBL] [Abstract][Full Text] [Related]
11. CTCF-dependent chromatin insulator is linked to epigenetic remodeling.
Ishihara K; Oshimura M; Nakao M
Mol Cell; 2006 Sep; 23(5):733-42. PubMed ID: 16949368
[TBL] [Abstract][Full Text] [Related]
12. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
13. Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs.
Flavahan WA; Drier Y; Johnstone SE; Hemming ML; Tarjan DR; Hegazi E; Shareef SJ; Javed NM; Raut CP; Eschle BK; Gokhale PC; Hornick JL; Sicinska ET; Demetri GD; Bernstein BE
Nature; 2019 Nov; 575(7781):229-233. PubMed ID: 31666694
[TBL] [Abstract][Full Text] [Related]
14. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
[TBL] [Abstract][Full Text] [Related]
15. IDH mutation impairs histone demethylation and results in a block to cell differentiation.
Lu C; Ward PS; Kapoor GS; Rohle D; Turcan S; Abdel-Wahab O; Edwards CR; Khanin R; Figueroa ME; Melnick A; Wellen KE; O'Rourke DM; Berger SL; Chan TA; Levine RL; Mellinghoff IK; Thompson CB
Nature; 2012 Feb; 483(7390):474-8. PubMed ID: 22343901
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analysis of the REST transcription factor regulatory networks in IDH mutant and IDH wild-type glioma cell lines and tumors.
Perycz M; Dabrowski MJ; Jardanowska-Kotuniak M; Roura AJ; Gielniewski B; Stepniak K; Dramiński M; Ciechomska IA; Kaminska B; Wojtas B
Acta Neuropathol Commun; 2024 May; 12(1):72. PubMed ID: 38711090
[TBL] [Abstract][Full Text] [Related]
17. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
18. Cancer: Oncogene brought into the loop.
Grimmer MR; Costello JF
Nature; 2016 Jan; 529(7584):34-5. PubMed ID: 26700812
[TBL] [Abstract][Full Text] [Related]
19. Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas.
Mo H; Magaki S; Deisch JK; Raghavan R
J Neuropathol Exp Neurol; 2022 Aug; 81(9):707-716. PubMed ID: 35856894
[TBL] [Abstract][Full Text] [Related]
20. CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP.
Moure CJ; Diplas BH; Chen LH; Yang R; Pirozzi CJ; Wang Z; Spasojevic I; Waitkus MS; He Y; Yan H
Mol Cancer Res; 2019 Oct; 17(10):2042-2050. PubMed ID: 31292202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]